此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

PROMET-BR - Molecular Profiling of Metastatic Prostate Cancer: a Brazilian Cohort (PROMET-BR)

2026年4月24日 更新者:AstraZeneca

A Retrospective and Prospective Study Aiming to Characterize Molecular Alterations and Clinical Outcomes of Metastatic Prostate Cancer in a Real-world Cohort of Patients Eligible to Palliative Systemic Therapy at Oncoclínicas & Co Group

PROMET-BR is an observational, retrospective and prospective real-world study in Brazil designed to characterize clinically relevant molecular alterations in metastatic prostate cancer and explore their association with patient outcomes in routine practice. The study will be conducted within Oncoclínicas & Co and will integrate centralized biomarker testing performed at OC Precision Medicine laboratories with retrospectively assembled clinical data from electronic health records (EHRs) from participating sites. Treatments are not assigned by the protocol; patients receive standard-of-care palliative systemic therapy at the discretion of their treating physicians.

研究概览

详细说明

PROMET-BR is an observational, retrospective and prospective molecular epidemiology study designed to characterize the prevalence of clinically relevant homologous recombination repair (HRR) gene alterations and PTEN loss of expression in metastatic prostate cancer in Brazil, and to describe associations between these biomarkers and real-world clinical outcomes.

The study is conducted within Oncoclínicas & Co and combines centralized biomarker testing performed at OC Precision Medicine (LOCUS lab, São Paulo) with retrospective clinical data assembled from electronic health records (EHRs) from participating Oncoclínicas & Co sites and integrated by the OC Precision Medicine Big Data team. The protocol does not assign or modify anticancer treatment; systemic therapies are delivered as standard of care at the discretion of treating physicians.

Approximately 100 adult patients (≥18 years) with a clinical diagnosis of metastatic prostate cancer receiving palliative systemic therapy at Oncoclínicas & Co (from 2023 onward) and with sufficient archived FFPE tumor tissue available will be included for the primary analyses. Both primary tumor and metastatic lesions may be used for tissue profiling, provided the patient has metastatic disease and is eligible for palliative systemic therapy. A prospective liquid biopsy subset of up to approximately 30 patients will be enrolled to support evaluation of plasma-based testing, including patients with tissue NGS failure/inconclusive results (expected in a proportion of cases due to pre-analytical tissue limitations) and/or patients enriched for known HRR alterations to enable comparative analyses.

Molecular assessments include a validated tissue NGS assay (GS Focus HRR) for HRR pathway alterations and a validated PTEN immunohistochemistry assay (Ventana PTEN, SP218) for PTEN expression status. For selected cases, a validated plasma NGS assay (GS Focus Liquid) will be performed to evaluate concordance with tissue results for key actionable HRR genes (including BRCA1, BRCA2, ATM, PALB2) and to provide an alternative approach when tissue testing is not informative. Clinical and outcome variables are derived from EHRs (including demographics, disease characteristics, treatment regimens and dates, discontinuation reasons where documented, and survival status). Exploratory endpoints include time to treatment discontinuation (TTD), time to next treatment (TTNT), and overall survival (OS), with subgroup analyses by clinically relevant features (e.g., de novo metastatic vs relapsed, hormone-sensitive vs castration-resistant, and metastatic burden definitions as available).

Analyses are primarily descriptive and exploratory. The primary analyses estimate biomarker prevalences with 95% confidence intervals, with planned stratified descriptions by clinical subgroups. Concordance between tissue and liquid biopsy results will be evaluated in participants with paired results, using concordance metrics (and, where applicable, sensitivity estimates). Exploratory time-to-event outcomes will be summarized using Kaplan-Meier methods and exploratory modeling approaches (e.g., univariate Cox models), acknowledging the heterogeneity of real-world clinical contexts and potential missingness in EHR-derived variables. The study is designed to provide robust local prevalence estimates of HRR alterations and PTEN loss using validated testing methodologies and to inform real-world feasibility considerations for biomarker testing in Brazil.

Ethics committee approval will be obtained prior to study conduct. Informed consent will be obtained where required (including for prospective liquid biopsy procedures); for certain retrospective situations (e.g., deceased or unreachable individuals), an ethics committee-approved consent waiver may be applied in accordance with local requirements. The study does not plan active adverse event collection; any safety information is limited to what is available in routine records for exploratory purposes (e.g., discontinuation due to toxicity when documented).

研究类型

观察性的

注册 (估计的)

100

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • São Paulo、巴西
        • Research Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

取样方法

非概率样本

研究人群

100 patients with metastatic prostate cancer receiving palliative systemic therapy at Oncoclínicas & Co will be recruited in the study. This will include retrospectively identified population with enough FFPE tissue available for tumor molecular analysis at OC Precision Medicine Lab who have started palliative treatment at OC clinics, as well as prospectively identified patients that are be eligible to tissue molecular profiling and will start treatment at Oncoclínicas & Co clinics. In parallel, we will prospectively recruit 30 patients in the liquid biopsy cohort, which will include patients known to have tumors with HRR mutations (based on GS Focus HRR or any other validated NGS assays) as well as those who had NGS tissue failure and have been prospectively recruited in the study.

描述

Inclusion Criteria:

  • Adult patients age >= 18 years; clinical diagnosis of metastatic prostate cancer (irrespective of hormone-sensitivity or castration-resistance status); eligible to palliative therapy for metastatic prostate cancer at Oncoclínicas & Co in 2023 onwards; sufficient FFPE tissue available for molecular profiling. For the subset of patients prospectively selected to liquid biopsy cohort, clinical or radiological evidence of disease progression at the sample collection, and with at least 14 days of treatment interval from last dose of systemic anticancer therapy or radiotherapy to liquid biopsy.

Exclusion Criteria:

  • No tissue FFPE tissue available for molecular profiling (except in prospective liquid biopsy cohort); less than 3 months follow-up from start of palliative therapy for metastatic prostate cancer at Oncoclínicas & Co.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
metastatic prostate cancer receiving palliative systemic therapy at Oncoclínicas & Co
The exposure/intervention under investigation is the use of archived FFPE tissue biopsy and/or newly acquired liquid biopsy for molecular profiling.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
prevalence of HRR mutations in tissue and/or liquid biopsy samples
大体时间:april 2026 to april 2027
to describe the prevalence of HRR mutations in tissue and/or liquid biopsy samples from metastatic prostate cancer using validated tissue next-generation sequencing (NGS) assays developed in-house at OC Precision Medicine;
april 2026 to april 2027
prevalence of PTEN loss of expression in tissue samples
大体时间:april 2026 to april 2027
to describe the prevalence of PTEN loss of expression in tissue samples using validated immunohistochemistry (IHC) assay Ventana PTEN (SP218) antibody.
april 2026 to april 2027

次要结果测量

结果测量
措施说明
大体时间
assess the analytical validity of a liquid biopsy NGS assay developed in-house
大体时间:april 2026 to april 2027
to assess the analytical validity of a liquid biopsy NGS assay developed in-house at OC Precision Medicine (GS Focus Liquid) as an alternative test to tissue NGS failure/inconclusive results
april 2026 to april 2027

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年4月30日

初级完成 (估计的)

2027年3月31日

研究完成 (估计的)

2027年3月31日

研究注册日期

首次提交

2026年4月24日

首先提交符合 QC 标准的

2026年4月24日

首次发布 (实际的)

2026年5月1日

研究记录更新

最后更新发布 (实际的)

2026年5月1日

上次提交的符合 QC 标准的更新

2026年4月24日

最后验证

2026年4月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

IPD 共享时间框架

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD 共享访问标准

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

IPD 共享支持信息类型

  • 研究方案
  • 树液

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅